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Copper in mitochondria
Copper (Cu) is an important catalytic element that drives a wide range of biochemical 
processes that are essential for life: energy generation, iron acquisition, oxygen transport, 
cellular metabolism, peptide hormone maturation, blood clotting and signal transduction 
[1]. The living organisms have developed a trafficking system of protein receptors and 
chaperons for the acquisition and disruption of copper to the target biomolecules in an 
efficient and safe way minimizing the negative effects of the element reactivity.  Although 
the copper trafficking system in cytoplasm of both prokaryotic [2,3] and eukaryotic cells [4]
has been extensively studied, the transfer of copper to mitochondria remains unclear.
Figure 1.1: Copper delivery and metallation of CcO and Sod1 within the IMS of eukaryotic cells. CcO is metallated by a 
pathway that consists of Cox17 and the co-chaperones, Sco1 and Cox11. Cox17 delivers copper to Cox11 for subsequent 
insertion into the CuB site in Cox1 and to Sco1/2 proteins (see §1.2.2) for insertion into the CuA site of Cox2. Copper is 
provided for SOD1 by Ccs1. Cox17 and Cox11 assess the matrix copper pool via an unknown  transporter. Reprinted 
from Cobine A. P. et al., BBA, 2006 [5].
Copper is required within the mitochondrion for the assembly of cytochrome c oxidase 
(CcO) and mitochondrial superoxide dismutase (Sod1). The copper-binding subunits of 
CcO are encoded by the mitochondrial genome, so copper insertion into CcO occurs within 
the organelle. Also Sod1 is imported as a metal-free polypeptide, so its activation occurs 
within the mitochondrial inter-membrane space (IMS) by Ccs1 (Cu chaperon of Sod). The 
presence of Ccs1 and two other Cu(I) chaperons (Cox17, Cox19 see §1.2.2) in both 
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cytoplasm and IMS make them candidates for shuttling copper ions to the mitochondrion 
but the unchanged levels of copper in yeast lacking the above proteins or tethering studies 
of the proteins in the IMS do not support this hypothesis [6-8]. Recent studies demonstrate 
that mitochondria serve as copper storage organelles where copper is present as soluble, 
low molecular weight non-proteinaceous Cu(I)-complex in the matrix. This form of copper 
is present also in the cytoplasm. It is suggested that this Cu(I)-complex can translocate 
(through an unknown transporter) from the mitochondrial matrix for subsequent use in 
CcO and Sod1 metallation [9] (Fig. 1.1). 
1.1 Cytochrome c Oxidase
Cytochrome c Oxidase (CcO) is a member of a superfamily of heme-copper-containing 
terminal oxidases that are present in all aerobic organisms [10]. In eukaryotic cells, CcO is 
the last enzyme of the energy transducing respiratory chain in mitochondria that catalyses 
the reduction of molecular oxygen and couples this reduction with proton translocation 
across the inner mitochondrial membrane (IM). It consists of twelve (yeast enzyme) to 
thirteen (mammalian enzyme) subunits, with the three subunits (Cox1–Cox3) forming the 
catalytic core encoded by the mitochondrial genome (Fig. 1.2). The remaining ten subunits
Figure 1.2: Crystal structure of bovine CcO. The mitochondrial-encoded subunits that make up the catalytic core of the 
enzyme are shown in blue (Cox1), red (Cox2) and yellow (Cox3). The nuclear encoded peripheral subunits are also 
shown. The cofactors: CuA, CuB, heme a, heme a3 and Zn cofactor are shown in space in the same orientation. 
Reprinted from Cobine A. P. et al., BBA, 2006 [5].
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are encoded by the nuclear genome and consist of small polypeptides that surround the 
catalytic core forming a dimeric enzyme buried in the lipid bilayer of the IM.
CcO requires many cofactors to be a functional enzyme; two heme groups, three 
copper ions, as well as one zinc, one magnesium, and one sodium ion (Fig. 1.2). Both 
hemes are localized at the Cox1, the first heme (heme a) is a six coordinate heme lacking 
the ability to bind ligands and is functional in electron transfer, the second (heme a3) is five 
coordinated heme with an open coordination where the oxygen binds. The heme a3 
interacts with a mononuclear copper site (the CuB site) during the catalytic reduction of the 
oxygen. Finally, in the Cox2 subunit is localized the CuA site, a copper bimetallic center 
which is exposed to the inter-membrane space (IMS). During the catalytic cycle, 
cytochrome c interacts with the CuA site, resulting a transfer of electron and oxidation of 
the cytochrome c. The formed electron gradient moves from the CuA site to the heme a  
and finally to the oxygen reduction center, heme a3-CuB. In total, four electrons are 
consumed in the reduction of one oxygen molecule and four protons are used from the 
matrix; coupled to this reaction is the translocation of four additional protons across the 
membrane to the IMS. The free redox energy is converted into a proton gradient which 
drives the synthesis of ATP [11-13]. 
1.2.1 Cytochrome c Oxidase assembly 
The CcO assembly is a complex process coordinated by two genomes 
(mitochondrial and nuclear) that requires the translocation and assembly of the subunits 
translated by the nuclear and mitochondrial ribosomes in the IM, the formation and 
insertion of the hemes, the delivery and insertion of the copper ions and finally the 
maturation of the enzyme. In this process about thirty accessory proteins have been 
identified necessary for the complex assembly [14]. 
Subunits translated in cytoplasm are imported as precursor polypeptides through 
the TOM complex (translocase of the outer membrane, OM) and a N-terminal 
mitochondrial target sequences direct these polypeptides to the TOM import pathway [15].
Protein import can also occur co-translationally from ribosomes attached to the outer 
mitochondrial surface at locations where the IM and OM form a contact. Translation of 
mitochondrially-encoded subunits (Cox1,Cox2 and Cox3) occurs within the matrix on 
ribosomes associated with the inner surface of the IM. Insertion of Cox1,Cox2 and Cox3 in 
the IM requires translocation of polypeptide segments across the IM by two conserved 
translocases, Oxa1 and Cox18 [16]. 
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In mammalian cells the assembly appears to occur in an ordered sequence of 
subcomplexes interaction, resulting the full maturation of the enzyme (Fig. 1.3). The 
assembly can be divided into four steps. At the first step, the Cox1 is inserted in the IM, 
where the heme cofactors are inserted by the interaction with Cox10/Cox15 (heme a
synthesis proteins [18,19]). The inner-membrane protein Surf1 (see §1.2.3) is possibly 
involved in heme a insertion or in the folding of Cox1 [20]. The first subcomplex is formed 
between Cox1 and Cox4. In the next step, the CuB-heme a3 site of Cox1 is formed and, 
simultaneously, Cox2 associates with Cox1 to stabilize the active site. At this stage is 
believed that the CuA site of Cox2 is also created. A number of proteins are involved in the 
copper insertion at two copper sites of the CcO, including Cox11, Cox17, Sco1 and Sco2 
(see. §1.2.2). In the final steps of the assembly, Cox3, Cox5a, Cox5b, Cox6b, Cox6c, 
Cox7c and Cox8 subunits become part of the subcomplex Cox1/Cox4/Cox2. The 
monomeric enzyme is formed when Cox6a and Cox7a subunits associate to Cox3 subunit. 
The assembly is completed with the holoenzyme dimerization [17]. 
Figure 1.3: Model of the assembly pathway of human CcO. I: Cox1, II: Cox2, III: Cox3, IV: Cox4, V: Cox5, VI: Cox6, 
VII: Cox7, VIII: Cox8, SURF1: Surf1, COX10: Cox10, Heam A: heme a, Heme A3: heme a3, SCO:Sco. Reprinted from
J.-Taanman, W and Williams, S. L., BST, 2001 [17].
1.2.2 Copper insertion to Cytochrome c Oxidase
Copper, zinc, and magnesium ions are necessary for CcO function. Apart from the 
structural role of the latter two metals, little is known about their delivery and insertion into 
CcO [21]. On the other hand, copper insertion in the two copper sites, CuA and CuB has been 
investigated in both prokaryotic and eukaryotic systems [22].
Cox11, Cox17, Sco1 and Sco2 have been recognized as the four proteins responsible 
for the copper insertion in an early stage of CcO assembly (Fig. 1.4). Cox17 has been 
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characterized as the mitochondrial Cu(I) chaperon, whereas Cox11, Sco1 and Sco2 
function downstream, for the copper insertion in Cox1 and Cox2 subunits.
COX17 was first identified in yeast as gene involved in copper metabolism and 
assembly [23]. Yeast lacking COX17 (COX17∆ yeast) are respiratory-deficient due to 
complete lack of CcO activity [24]. This phenotype is reversed by the addition of copper to 
the growth medium. This result is consistent with Cox17 functioning in copper delivery to 
CcO. This was strengthened by the observation that Cox17 is a copper binding protein [25]. 
Moreover, when as fusion protein Cox17 was directed and tethered to the IM by 
mitochondrial import sequence and transmembrane segment of Sco2 was able to reverse 
the respiratory defect of COX17∆ cells and restored normal CcO activity [26]. This result
indicates that the copper chaperone function of Cox17 is confined into IMS [27].
Figure 1.4: Structural representation of the copper-delivery pathway. The crystal structure of Cox1, Cox2 and Sco1 are 
shown with the solution structures of Cox17 and Cox11. Arrows depict the copper transfer from Cox17 to Cox11 and 
Sco1 and onto Cox1 and Cox2, respectively. Reprinted from Cobine A. P. et al., BBA, 2006 [5].
Cox17 contains six conserved cysteines, and has a coil-helix-coil-helix (CHCH) 
motif [28]. The four cysteines that have a CX9C motif form two structural disulfide bonds. 
Cox17 was found to form two distinct Cu(I) functionally important conformers. One Cu(I) 
conformer consists of a single Cu(I) coordinated to a monomeric protein stabilized by two 
disulfide bonds and a second Cu(I) conformer is an oligomeric protein complex 
coordinating a polycopper–thiolate cluster. Interestingly, in vitro experiment showed that 
only the monomeric conformer can transfer Cu(I) to Sco1, suggesting that this form is the 
active state in the copper transfer within the IMS [29]. 
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The translated Cox17 is detected both in cytoplasm and IMS [6]. This dual 
localization of Cox17 led first to the suggestion that Cox17 can transfer Cu(I) ions across 
the OM. However, COX17∆ cells are not deficient in mitochondrial Cu, suggesting that 
Cox17 is not the primary mitochondrial copper shuttle. The metallation pathway of this 
chaperon is still unclear. The recent discovery of the matrix copper pool (as soluble, low 
molecular weight complex) suggests a model where copper is delivered from matrix to 
IMS [8]. Cox17 is suggested to be translated in the cytoplasm with a molten globule 
structure of a fully reduced state [30]. The protein translocation in the IMS follows the 
folding traps pathway [31] similarly to other small proteins that are localized in the IMS. 
Following its translocation across the OM, the precursor form is bound by the IM protein 
Mia40 catalyzing the formation of the structural disulfide bonds [32,33].
Sco1 was first implicated in copper delivery to CcO by the observation that the 
respiratory deficient phenotype of a Cox17 yeast mutant (Cox17 harboring a Cys Tyr 
substitution) was suppressed by overexpression of SCO1 or a related gene designated 
SCO2 [34].Yeast strains lacking SCO1 are also respiratory deficient, and an excess of 
copper and/ or overexpression of either Cox17 or Sco2 can not compensate for the Sco1-
associated CcO deficiency [35]. The requirement of Sco1 in the activation of CcO indicates 
that Sco1 functions downstream from Cox17 in the delivery of copper to CcO. Indeed, in 
vitro showed that Sco1 can receive copper from the copper chaperone Cox17 [36]. A 
transient complex with Cox2 with yeast Sco1 confirmed the importance of Sco1 in 
formation of the CuA site 
[37].
Sco1 and Sco2 are highly similar proteins but their distinct role in eukaryotic cells 
is still unclear. Both proteins contain a single transmembrane α-helix at the N-terminal 
segment of the proteins, anchoring these two proteins to the inner mitochondrion while the 
C-terminal segment of Sco proteins is soluble and extended into IMS. Copper ion is bound 
by the two cysteins of the highly conserved CXXXC motif and His residue [38]. Mutation of 
any one of these conserved residues in Sco1 abrogates function, resulting in a 
nonfunctional CcO complex, which means that the function of Sco1 correlates with Cu(I) 
binding. Moreover, studies with immortalized fibroblasts from Sco1 and Sco2 patients 
suggest that human Sco1 and human Sco2 have non-overlapping but cooperative functions 
in CcO assembly [39]. Recently, it was shown that human Sco2 is also the downstream 
mediator of the balance between the utilization of respiratory and glycolytic pathways and 
has a regulatory role in the maintenance of cellular copper homeostasis [40]. In human 
patients with mutations in the Sco2 gene have a clinical phenotype distinct from that of 
Sco1 patients (Sco2 patients present with neonatal encephalocardiomyopathy, whereas 
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Sco1 patients exhibit neonatal hepatic failure), even if Sco1 and Sco2 are ubiquitously 
expressed and exhibit a similar expression pattern in different human tissues [41]. 
Structurally both proteins are characterized by a thioredoxin fold and with a single 
Cu(I) ion bound to be solvent exposed and poised for a ligand exchange transfer reaction. 
The higher structural flexibility of Sco2 compared to Sco1, especially in its apo form, is 
suggested to be important for different protein-protein interaction pathways [42]. In addition 
to Cu(I) binding, Sco proteins bind also Cu(II) [42-44]. The Cu(II) site has a higher 
coordination number than the three-coordinate Cu(I) site [45]. Replacement of Asp238 in 
yeast Sco1 abrogated Cu(II) coordination and led to a non-functional protein [46]. These 
data suggest that copper binding can be critical for normal Sco1 function.
They are mainly three scenarios concerning the function of the Sco based on 
different observations: 1) Human Sco function as a complex to transfer two coppers to the 
CuA site. This is supported by the dominant-negative effect on CcO activity of the 
overexpression of either gene in the reciprocal patient cell line and that the full-length 
proteins are homo-oligomers in vivo [37,47]. It is possible that a Sco1/Sco2 complex may 
induce one protein to catalyze the oxidation of a Cu(I) to Cu(II) enabling the complex to 
simultaneously transfer both Cu(I) and Cu(II). Alternatively, an additional assembly factor 
may be required for Cu(I) oxidation. Otherwise, two successive Cu(I) transfers yield a 
reduced CuA site that can be converted to the oxidized, mixed valent site through electron 
transfer within the assembly complex [46]. 2) Sco were suggested to function as a redox 
switch, in which oxidation of Cu(I) to Cu(II) induces release of the Cu(II) ion thereby 
permitting the two thiolates to participate in a peroxidase reaction [45]. Since Cu(II) is 
stably bound by Sco, a role for Sco proteins as peroxidases is not compelling. 3) The 
structural resemblance of Sco1 to peroxiredoxins and thioredoxins raised the possibility 
that Sco proteins may function as a thiol:disulfide oxidoreductase to maintain the CuA site 
cysteines in the reduced state ready for metallation [45]. The disulfide exchange with Cu(I) 
insertion between oxidized CuA site and Cu(I)Sco, was suggested by the observation of 
Ni(II) located at the binding site of the human Sco crystal structure with oxidized cysteines 
[48]. Recently, has been shown that indeed in prokaryotic organisms, Sco1 is able to reduce 
oxidized CuA, while does not transfer Cu(I) to it. Thus its role is, in prokaryotic organisms, 
that of assisting the copper transfer process maintaining the copper bridging Cys of CuA in 
a reduced state [49].
Cox11 is the co-metallochaperone for the CuB site (Fig. 1.4). Recently, was 
demonstrated that the CuB site is absent in CcO purified from Rhodobacter sphaeroides
lacking Cox11 gene [50]. Moreover, it is shown that some Cox11 mutants lack CcO activity; 
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however, RNA and protein synthesis of the core subunits Cox1 and Cox2 are normal, 
suggesting that Cox11 functions post-translationally to generate active CcO [51]. Yeast 
Cox11 is a 34 kDa protein that resembles Sco1, with a single transmembrane α-helix 
downstream of the N-terminal mitochondrial targeting sequence. The C-terminal domain 
exposed to IMS, similarly to the soluble C-terminal domain of Sco1, binds one Cu(I) ion. 
There is only one structure available of soluble domain of Cox11 (from Sinorhizobium 
meliloti) showing that the domain is organized into a immunoglobulin-like fold and Cu(I) 
ion is bound to the putative copper binding motif CFCF (Fig. 1.3) [52]. Similarly for Sco, 
the mechanism of the insertion of copper to CuB by Cox11 is an unresolved question 
especially how the CuB site is formed when is buried 13 Å below the membrane surface.
1.2.3 The role Surf1 protein in CcO assembly
The human SURF1, the first gene of the surfeit gene locus (a highly conserved cluster 
of six housekeeping genes) codes for a 30 kDa protein that is involved in CcO assembly. 
Located in the IM, Surf1 contains two transmembrane α-helices and a large connecting 
domain facing the IMS [53]. Mutations in the SURF1 are responsible for the Leigh 
syndrome, a fatal neurological disorder associated with severe CcO deficiency, where all 
tissues show a loss of CcO activity between 80–90% [54]. Sequence alignments revealed 
many Surf1 homologues in eukaryotes and prokaryotes. They show a striking degree of 
homology, and all proteins exhibit the same characteristic transmembrane α-helix topology 
and two highly conserved regions in the domain facing the IMS [55].
The yeast Surf1 homologue, Shy1 has been discovered and characterized in 
connection with yeast mutants and deletions of the gene leading to reduced oxidase 
activity, likely as the amount of CcO is highly decreased in mutants. The remaining 
enzyme behaves enzymatically and structurally like wild type, suggesting Shy contributes 
to the assembly or the stabilization of CcO [56]. Further experiments on SHY1 mutants 
revealed that specifically steady-state levels of Cox1 were decreased, suggesting that Shy1 
promotes the formation of an assembly intermediate consisting of Cox1/Cox2 [57]. 
Moreover, it has been shown that Shy1p interacts with Mss51 (a transcriptional activator of 
Cox1), Cox14 (CcO assembly factor) and associates with CcO subunits in the assembly 
subcomplexes [58]. In bacteria, the effect of Surf1 homologue gene deletion was studied in 
Paracoccus denitrificans and Rhodobacter sphaeroides. The former bacterium contains 
two Surf1 homologues (Surf1c and Surf1q) that act independently for the assembly of the 
aa3-type CcO and the ba3-type quinol oxidase, respectively. The latter bacterium 
synthesizes an aa3-type CcO. The biochemical features of the individual assembled oxidase 
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suggest that Surf1 plays a role in facilitating the insertion of heme a3 (direct or indirect) 
into the Cox1 where the formation of the heme a3-CuB center is a limiting step for the 
interaction of Cox1/Cox2 [59,60].
1.3 Aims and topics of the research
In my three-year PhD course, research was focused on the investigation of the function 
of proteins involved in the assembly and insertion of metal cofactor in an early state of 
CcO maturation. In particular, I focused my attention on metalloproteins involved in the 
formation of the CuA site and on Surf1 protein that is suggested to play a role in the folding 
and insertion of heme a3 in Cox1 subunit. 
The mitochondrial metallochaperon Cox17, transfers copper to both Sco1 and Sco2 
proteins for subsequent insertion of Cu(I) ions into the CuA. In order to clarify the copper 
exchange mechanism between the Cox17 and the Sco proteins, we investigated their 
interactions as far as copper and electron exchange. The scenario where the two Sco 
proteins oligomerize and interact forming a complex able to facilitate two copper ions into 
the CuA site was also investigated. Moreover, the full length Sco1 and Sco2 α-helical 
trasmembrane proteins were subjected to expression and purification trail.
Surf1 is a protein showing sequence conservation from human to prokaryotes, involved 
in the assembly of CcO. Apart from observations concerning the relationship of the Surf1 
with the Leigh syndrome, interaction with Cox1 or other subcomplexes, the role of the 
protein is still being speculative and there is no structural information. In order to 
structurally characterize Surf1, the soluble domains from human and bacteria as well as the 
full length protein containing the two transmembrane α-helices, were produced and 
purified.
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2. Methodological aspects 
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2.1 Bioinformatics for protein expression
Bioinformatics has an essential role in understanding genomic and proteomic data, and 
in organizing experimental data. It is an interdisciplinary research area at the interface 
between the biological and computational science. 
A number of data banks are available and provide the scientific community with tools 
for searching gene banks, for the analysis of protein sequences, for the prediction of a 
variety of protein properties. Databases contain information and annotations of DNA and 
protein sequences, protein structures and protein expression profiles. The most used 
databases are:
a) NCBI: is a web site which integrates information from several databases 
(Swissprot, EMBL and all geneBank). [www.ncbi.nlm.nih.gov/Entrez/], 
b) PDB: A 3-D biological macromolecular structure database. [www.rcsb.org/pdb], c) 
Pfam: is a collection of different protein families organized in terms of different domains 
as obtained from multiple alignment. [http://pfam.wustl.edu], 
d) PROSITE: is a database of protein families and domains. It is based on the 
observation that, while there is a huge number of different proteins, most of them can be 
grouped, on the basis of similarities in their sequences, into a limited number of families. 
Proteins or protein domains belonging to a particular family generally share functional 
attributes and are derived from a common ancestor. [www.expasy.org/prosite/], 
e) STRING: is a database of known and predicted protein-protein interactions. The 
interactions include direct (physical) and indirect (functional) associations [www.dag.embl-
heidelberg.de].
All bioinformatics data is stored in the above databases and can be browsed by 
bioinformatics tools for extracting information of a given target or targets. The most used 
programs for gene or protein browsing are: 
a) BLAST (The Basic Local Alignment Search Tool): finds regions of local similarity 
between sequences. The program compares nucleotide or protein sequences to sequence 
databases and calculates the statistical significance of matches. BLAST can be used to 
infer functional and evolutionary relationships between sequences as well as help identify 
members of gene families. [www.ncbi.nlm.nih.gov/BLAST/]. 
b) CLUSTALW: is a general purpose multiple sequence alignment program for DNA 
or proteins. It produces biologically meaningful multiple sequence alignments of divergent 
sequences. It calculates the best match for the selected sequences, and lines them up so that 
the identities, similarities and differences can be seen.  [www.ebi.ac.uk/clustalw/]
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Once selected a protein target of particular interest is subjected to further 
bioinformatics investigations. In case where the target will be used for recombinant protein 
expression the following characteristic of the protein can predicted and be used for 
defining constructs: 
a) Post-translational modification prediction: signal peptides, glycosylation, 
phosphorylation and cleavage sites: TargetP [1], SIGNALP [1]. 
b) Topology prediction of transmembrane (TM) regions:  prediction of membrane-
spanning regions and their orientation: TMHMM  [2]; TMpred [3], HMMTOP [4]. 
c) Secondary structure prediction: of the regions with tendency to form helices, beta-
sheet, coil or turns. Combining these predictions with homologue proteins alignment, can 
be used to select the exact residues that define a construct minimizing the possibility of 
destroying a region with certain secondary structure. NPS@ [5]. 
d) Prediction of intrinsically unstructured /disordered regions: recognition of such 
regions from the amino acid sequence based on the estimated pairwise energy content. The 
underlying assumption is that globular proteins are composed of amino acids which have 
the potential to form a large number of favorable interactions, whereas intrinsically 
unstructured proteins adopt no stable structure because their amino acid composition does 
not allow sufficient favorable interactions to form. IUPred [6]. 
e) Rare codon calculation: Over-expression of recombinant protein in E. coli may be 
severely diminished (to the point of being undetectable) if the ORF that codes for the 
protein uses "rare" codons that are infrequently used by E. coli. In particular, codons for 
arginine (AGG, AGA, CGA), leucine (CTA), isoleucine (ATA), and proline (CCC) may be 
a problem. RaCC [7].
Figure 2.1:  Flow chart for definition of human Surf1 
protein soluble domain and identification of bacterial Surf1 
homologues with single TM α-helix. Abbreviations: TM, 
transmembrane, SS: secondary structure
In the present thesis, Surf1 protein was chosen as 
a target (see §1.3). Before cloning and production 
of the protein was necessary a bioinformatics
investigation. In the Fig. 2.1 is shown a flow chat 
of the general idea followed in order to define the 
soluble domain of the protein. Using a multi 
alighment of the eukaryotic proteins and their secondary structure (SS) prediction in 
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combination with the predicted TM regions, the soluble domain of human protein between 
the two TM regions (one at each terminus) was predicted from 74Q-294Y (see §3.4). For 
the expression of the mature human Surf1 (see §3.4) lacking the mitochondrial signal 
peptide, the cleavage site was predicted at the 45C residue. In order to select a bacterial 
Surf1 for expression, we browsed the homologues proteins looking for proteins with a 
single TM region. Under this criterion three bacterial proteins where identified: 1) 
Caulobacter crescentus: single TM at C-terminus, 28.18% identity to the human Surf1 2) 
Methylobacterium chloromethanicum (CC): single TM at C-terminus , 25.88% identity to 
the human Surf1 Sinorhizobium meliloti (SM): single TM at N-terminus , 22.92% identity
to the human Surf1. The two of the three proteins (CC, SM) were further studied for the 
definition of the soluble domain similarly to the human Surf1.  Moreover, the human Sco 
proteins where also investigated as far as the definition of the full length constructs (see 
§3.4) but also for the sequence conservation of the transmembrane α-helix and charged 
region at the C-terminal of the transmembrane α-helix (see §3.3).  
2.2 Gene cloning
Gene cloning involves molecular biology techniques for the amplification of a DNA 
construct, purification of DNA construct or vectors, insertion of gene to vectors and finally 
sequencing of the gene for verifying the correct insertion and absence of mutations. 
The first step of the cloning process consists in the amplification of target gene from 
cDNA (synthetic or extracted from the organism of interest) or plasmids via PCR 
(Polymerase Chain Reaction) using primers. After purification, the amplified product is 
inserted into a specific expression vector using one of the methods described below. 
The classic method to insert a gene in a vector is using restriction enzymes that cleave 
DNA at specific recognition sites. To be able to clone a DNA insert into a cloning or 
expression vector, both have to be treated with two restriction enzymes that create 
compatible ends. The next step is the ligation of the insert into the open vector. This 
involves the formation of phosphodiester bonds between adjacent 5'-phosphate and 3'-
hydroxyl residues, a reaction catalyzed by the bacteriophage T4 DNA ligase. Finally an 
aliquot of this reaction is transformed in DH5α E. coli competent cells and positives clones 
are screened both by PCR and DNA sequencing. The yield of this procedure depends on 
the efficiency of the ligation step which is affected by the DNA concentration, the 
vector/DNA insert ratio and the transformation efficiency of the cells. Moreover the 
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parallelization of this approach is not so easy because not all the host vectors and the target 
genes can be cleaved by the same restriction enzymes.
Figure 2.2: (left) The flexibility of the Gateway Technology. After cloning the gene of interest into the Entry 
vector, you can transfer the gene of interest simultaneously into multiple destination vectors. (right) The 
mechanism of the gene ligation by Topoisomerase I. Reprinted from Gateway Technology handbook.
The other cloning strategy exploits the Gateway Cloning System (Fig. 2.2) from 
Invitrogen, a universal cloning method that takes advantage of the site-specific 
recombination properties of bacteriophage lambda [8]. Mainly it consists in the creation of a 
common entry vector that can be recombined in several compatible vectors without the use 
of any restriction enzyme. The entry vector can be obtained via a ligation reaction of the 
entry vector with DNA construct amplified; the reaction is catalyzed by the topoisomerase 
I (Fig. 2.2). After isolation of the entry vector, the second step is to generate an expression 
vector by performing a recombination reaction between the entry clone and a Gateway 
destination vector of choice.
In the present thesis as cloning system was used mainly the Gateway Cloning System, 
by insertion of the DNA constructs in the pENTR/TEV/D-TOPO vector and recombination 
to expression vectors: pETG-30A (His-GST), pDEST-17/O (His), pDEST-20 (His-Trx), 
pDEST-His-MBP, pDEST-His-MBPperi, pETG-60A (His-NusA) and pTH34 (His-GB1). 
The HSco1L (see §3.3) construct was amplified by PCR using the cDNA of human SCO1
(purchased from RZDB, Germany). The construct was inserted in Gateway Entry vector 
pENTR/TEV/D-TOPO (Invitrogen) and sequence was verified by sequencing at PRIMM 
(PRIMM, Italy). The pENTR clone was recombinated with pETG-30A (6His-GST). A 
_________________________________________________________________________
_________________________________________________________________________21
similar procedure was followed for the cloning of the full length proteins Sco1, Sco2 and 
Surf1 (see §3.4).
2.3 Recombinant protein production
Several host systems are available for protein production, including bacteria, yeast, 
plants, fungi, insect and mammalian cells. The choice strongly depends upon the specific 
requirements of the target protein. 
Often the first choice is the E. coli system, since it is the easiest, quickest and cheapest 
expression system. There are many commercial and non-commercial expression vectors 
available with different N- and C-terminal tags and many different bacterial strains which 
are optimized for special applications. Moreover one of the major advantages of E. coli is 
that the production of isotope labelled protein for NMR, is less complex compared to other 
systems. However, E. coli is a prokaryote and lacks intracellular organelles, such as the 
endoplasmic reticulum and the Golgi apparatus that are present in eukaryotes, which are 
responsible for protein post-translation modifications. Many eukaryotic proteins can be 
produced in E. coli but sometimes they are produced as non-functional inclusion bodies 
protein, since glycosylation or post-translational modifications such as proteolytic 
processing, folding and disulfide bond formation do not occur. Therefore, researchers have 
recently turned to eukaryotic yeast and insect cell expression systems for protein 
production.
2.3.1 Recombinant proteins production in E.coli.
Similarly to gene cloning, also for protein production the best strategy is the use of a 
parallel expression strategy; depending on the number of targets the possible choices are: 
(i) to express more genes in the same bacterial strain, (ii) to express a single gene in 
different strains or (iii) to express more genes in different strains.
A preliminary expression test is performed in a small-volume scale using three strains 
(e.g.: Bl21(DE3)pLysS a protease deficient strain, Rosetta(DE3) for rare codons containing 
genes and Origami(DE3) for disulphide containing proteins), three expression temperatures 
(37-25-17°C), three inducer (arabinose or isopropyl-beta-D-thiogalactopyranoside) 
concentrations, different induction times (4h and 16h) and three culture media of different 
composition. Expression results are checked on SDS polyacrylamide gel (SDS-PAGE). 
This kind of approach allows to explore a large set of expression conditions and to evaluate 
which one gives the best yield of soluble protein.  
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In case of negative or partially positive results some or all variables can be modified, in 
particular the more influencing ones like the choice of bacterial strain, the induction times, 
the kind of vectors and expression promoters used. If the main fraction of the protein is 
produced in the insoluble fraction, refolding trials can be performed (see §2.5). The last 
choices are to redesign the expressed domains or to use another expression system. 
In dependence of the spectroscopic technique of choice, protein expression is 
performed in differently composed media. In fact, when large amounts of proteins must be 
isolated for techniques that do not require isotopic labelling, the culture is usually 
performed in a so-called rich or complex medium. Rich media contain water soluble 
extracts of plant or animal tissue (e.g., enzymatically digested animal proteins such as 
peptone and tryptone), and for this reason are rich in nutrients and minerals, assuring a fast 
bacterial growth and a high expression level. Their exact composition is unknown and this 
can impair the reproducibility of cultures. Chemically defined (or minimal) media are 
composed of pure ingredients in measured concentrations, dissolved in purified water; this 
way the exact chemical composition of the medium is known, allowing high 
reproducibility of protein yields. Typically, this class of media is composed of a buffering 
agent to maintain culture pH around physiological values, a carbon source like sugar 
(glucose) or glycerol, and an inorganic nitrogen source, usually an ammonium inorganic 
salt. Depending on the bacterial strain and the expressed proteins various mineral salts can 
be added and, if necessary, growth factors such as purified amino acids, vitamins, purines 
and pyrimidines. Chemically defined media are easier to isotopically enrich, simply by 
using 15N and 13C enriched nitrogen and carbon sources.
In the current thesis, the soluble domain of the HSco1 (two constructs, see §3.3) and 
HSco2 (two construct, see §3.3) were expressed in BL21-Gold(DE3) and BL21-(DE3)
Codonplus, respectively. Growth conditions were the same to the ones already reported [9]. 
2.3.2 Integral membrane  proteins production in E.coli
Membrane protein production in E. coli can take place in at least two states: a 
functional state involving protein insertion into the bacterial membrane or in an inactive 
state where the protein usually exists in inclusion bodies as an insoluble aggregate. In cases 
where fusion tag is used, the protein can be also soluble.
Targeting expression of hydrophobic membrane proteins into inclusion bodies 
would be preferable to membrane insertion as protein purification from membranes can be 
labor-intensive. Furthermore, targeting membrane proteins to inclusion bodies also has 
many advantages over membrane insertion. Inclusion bodies may serve to shield cells from 
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toxic effects of the expressed protein, resulting in higher protein yields. Also, as the 
expressed protein is the primary component of the inclusion body, protein purification is 
simplified to the isolation of the inclusion bodies. However, the major downside of this 
expression method is that following purification, the protein must be refolded to its native 
state. In addition, lipids or detergents may be required during purification to maintain 
protein solubility due to the hydrophobic nature of these proteins, which can impose 
complications to purification procedures [10].
A bacterial expression procedure used with considerable success is expression of 
membrane proteins as fusion constructs. The E. coli maltose-binding protein (MBP) and 
thioredoxin (Trx) along with glutathione S-transferase (GST) from Schistosoma japonicum
are the most widely used fusion systems and can facilitate solubility, limit toxicity, 
decrease proteolysis, and aid in purification of proteins. While GST and MBP are 
advantageous as fusion partners because of their high bacterial expression levels and 
affinity purification capacity, Trx is considered a useful fusion protein for hydrophobic 
proteins because of its high aqueous solubility [11]. 
Altering the expression medium, temperature and concentration of inducer can also 
aid membrane protein expression. 
The commercially available BL21 E. coli is the most commonly used bacterial host 
for heterologous expression as it is protease deficient and is known to promote plasmid 
stability. BL21 derivatives with considerable success at overexpressing membrane proteins 
normally toxic to the cells are the Avidis C41 (DE3) and C43 (DE3) strains (Saint-
Beauzire, France). While the genetic mutations resulting in improved protein expression is 
unknown, current hypothesis suggest the mutations performed may affect the amount of T7 
RNA polymerase production [12]. 
In the present thesis, production of transmembrane proteins (HSurf1, HSco) was 
detected in the soluble fraction, in the cell membranes and in inclusion bodies. The 
production in the cell membranes and the conditions used are described in the §3.4.
2.4 Protein purification
The strategy of purification depends mainly upon the localization of the produced 
protein within the host; for example the protein can be secreted into the growth media, 
transported in the periplasmic space or produced like a soluble or insoluble (inclusion 
bodies, IBs) protein within the cytoplasm and finally directed to the cell membranes. In 
each of the cases the isolation has to be performed in different ways.
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Cell lysis is the first step in protein purification and the technique chosen for the 
disruption of cells must be compatible with the amount of material to be processed and the 
intended downstream applications. Many techniques are available, spanning from physical 
to detergent-based methods. Among the first class are mechanical disruption, liquid-based 
homogenization, such as the French press, where cells are lysed by forcing the suspension 
through a narrow space, and sonication, which uses pulsed, high frequency sound waves to 
agitate and lyse cells. Gentler ways of disrupting cells are freeze-thaw lysis, detergent 
lysis, enzymatic lysis and osmotic lysis. The latter method is well suited when the protein 
is expressed in the periplasm of the cell. The big advantage of this technique is that all the 
interferents coming from the cytoplasmic region are eliminated, since the inner membrane 
is not broken, preventing also genomic DNA and proteases release. 
The following step of purification procedure is composed of normally two or more 
rounds of chromatography, playing on the different physical chemical and biological 
characteristics of the protein. A powerful chromatographic technique is Ion exchange 
chromatography (IEX) that separates the proteins on the basis of a reversible interaction 
between the polypeptide chain and a specific, charged ligand attached to a
chromatographic matrix. The sample is applied in conditions that favour specific binding, 
e.g. low ionic strength of the solution and carefully calibrated pH, in order to enhance 
interaction with the target of interest. The unbound material is washed away, then the 
bound protein is recovered by changing conditions to those favouring desorption. This can 
be achieved by changing pH or ionic strength of the eluant. The most used resin is the 
anionic one, since the majority of proteins carry an overall net negative charge at 
physiological conditions. 
Size-exclusion chromatography (SEC) is the simplest and mildest of all the 
chromatographic techniques; the support for gel filtration chromatography is composed of 
beads which contain holes, called "pores," of given sizes. Larger molecules, which can't 
penetrate the pores, move around the beads and migrate through the spaces which separate 
the beads faster than the smaller molecules, which may penetrate the pores; in this 
technique the buffer composition does not play any role in the resolution. SEC can be 
performed on a “rough” level, separating the components of a sample in major groups to 
remove for example high or low molecular weight contaminants or to exchange buffers, 
while high resolution fractionation of biomolecules allows to isolate one or more 
components of a protein mixture, to separate monomers from aggregates, to determine 
molecular weights or to perform a molecular weight distribution analysis, provided that 
suitable standards are available.
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In case of peptide fusion tags, a variety of affinity purification methods are available. 
The basic principle is that the protein tag specifically interacts with an affinity resin and 
binds the tagged protein whereas other polypeptides (impurities) are not bound. This 
allows a simple purification by releasing the tagged protein with a suitable competing 
buffer. In this case, usually an intermediate purification step includes the cleavage of the 
fusion tag with proteases such as enterokinase, Factor Xa, thrombin or Tobacco Etch Virus 
(TEV) depending on the cleavage site. The protease recognition site is selected and cloned 
in the vector codifying for the protein sequence at the cloning step; pilot experiments 
should be done to find out suitable cleavage conditions. The fusion protein is then 
separated, either with a second round of affinity purification, or by SEC when favoured by 
the size difference. 
Figure 2.3: Purification of HSco, LHSco and Surf1/Sco TM proteins. Abbreviations: HSco: short constructs 
of the soluble domain of human Sco1 (G132- 301S) and Sco2 (100G-266S), LHSco: longer constructs of the 
soluble domain of human Sco1 (113K-301S) and Sco2 (79R-266S), Surf1/Sco TM proteins: see §3.4, IMAC: 
Immobilized Metal Ion Affinity Chromatography, SEC: Size-exclusion chromatography. 
Currently Immobilized Metal Ion Affinity Chromatography (IMAC) is the most used 
affinity technique; it exploits the interaction between chelated transition metal ions 
(generally Zn(II),  Ni(II) and Co(II) ) and side-chains of specific amino acids (mainly 
histidine) added on the protein. In IMAC chromatography, the target protein is usually 
washed from the impurities and eluted using increasing concentration of imidazole, which 
acts as competitive agent. Histidine-tagged (6His-tag) proteins can also be eluted from the 
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column lowering the pH to decrease the binding affinity or stripping the metal ions from 
the column with EDTA. 
In the present thesis two soluble constructs for each HSco1 and HSco2 have been used. 
The purification of the short constructs (human Sco1 (G132- 301S) and Sco2 (100G-
266S)) has been already reported [9]. These constructs has been used for the interaction 
with Cox17 (see §3.2). Two longer constructs of HSco, Sco1 (113K-301S) and Sco2 (79R-
266S), have been used for the dimerization studies (see §3.3). The purification of the 
proteins is shown on Fig. 2.2., which involves mainly purification by IMAC (His-trap 
column charged with Zn(II) ). The longer constructs purification involves an addition step 
of SEC. Moreover the general purification of the transmembrane proteins (see §3.4) is also 
shown on Fig. 2.3. 
2.5 Protein refolding
Heterologous expression of foreign genes in E. coli often leads to production of the 
expressed proteins in IBs. IBs must then be solubilized and refolded into an active 
conformation. Refolding of IBs is not a straightforward process, often requiring an 
extensive trial-and-error approach. There are two important issues in recovering active 
proteins from IBs, i.e., solubilization and refolding. Solubilization must result in 
monomolecular dispersion and minimum non-native intra- or inter-chain interactions. 
Choice of solubilizing agents, e.g., urea, guanidine HCl, or detergents, plays a key role in 
solubilization efficiency, in the structure of the proteins in denatured state, and in 
subsequent refolding [13].
Refolding is initiated by reducing concentration of denaturant used to solubilize 
IBs. Protein refolding is not a single reaction and competes with other reactions, such as 
misfolding and aggregation, leading to inactive proteins. Rate of refolding and other 
reactions is determined both by the procedure to reduce denaturant concentration and the 
solvent condition. The procedures to reduce the denaturant will be shortly described below:
a) One-step dialysis: Denatured, unfolded protein samples in concentrated denaturant 
solution are dialyzed against a refolding buffer, and hence, exposed to descending 
concentration of the denaturant. b) Step-wise dialysis: This protocol uses descending 
concentration of denaturant for dialysis and has been successfully used for refolding 
antibodies. Unfolded protein sample is initially brought to equilibrium with high 
denaturant concentration, then with middle concentration, and with low concentration. c)
Buffer-exchange by gel filtration: Gel filtration column is equilibrated with the final 
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refolding buffer. Unfolded protein sample in denaturant is applied to the column and run 
through it with the refolding buffer. Use of desalting column will separate proteins from 
denaturant, while use of protein-sizing column will fractionate protein species. d) Dilution: 
Protein samples at high denaturant concentration are delivered into a large volume of 
refolding buffer. Dilution brings the unfolded sample into a rapid collapse, whereby 
bypassing the intermediate denaturant concentration. e)  Solid phase refolding: Denatured 
protein is initially non-covalently bound to solid   matrix such as Ni-resin or ion-exchange 
resin in the presence of denaturant. Denaturant concentration is then decreased to initiate 
refolding. Since protein molecules are bound to resin, this procedure minimizes 
aggregation of unfolded protein or folding intermediates. 
During my PhD studies, the production of the soluble domain of human Surf1, 100A-
255G, and the soluble domain bacterial of Surf1 (Caulobacter crescentus, 107G-276P, 
Sinorhizobium meliloti, 101A-262E) showing that the proteins are expressed in inclusion 
bodies. Refolding involved purification under denaturing conditions followed by refolding 
procedures: dilution, step-dialysis and solid phase refolding (IMAC).
2.5.1 Membrane protein refolding
Membrane proteins expressed as inclusion bodies can be refolded in the presence of 
detergents following strategy similar to soluble protein refolding. In lack of a detailed 
theoretical understanding of the various factors affecting refolding yields and tendency to 
aggregate, the most straightforward strategy to find suitable folding conditions is to vary 
all the parameters, especially the composition of detergent/lipid micelles, in a systematic 
way and quantify the refolding yield. A proper functional assay that works in detergent is 
therefore a crucial success factor [14].
During my PhD thesis, I tested the refolding of the HSco1 protein containing the 
transmembrane helix (THSco1, see §3.4). Refolding was performed according to the 
protocol of Opella et al. [15], were the protein was extracted from IBs by a harsh detergent 
(Empigent BB) followed by column refolding and detergent exchange. The refolding was 
followed by NMR and CD spectroscopy.
2.6 Sample preparation
Human Sco (HSco) proteins metallation protocol is already reported [9]. Protein 
reduction and metallation were carried out under nitrogen atmosphere in an anaerobic 
chamber to prevent oxidation of the cysteine residues. Dithiothreitol (DTT) was added to 
the protein in a 10mM concentration to reduce the cysteine residues in the CXXXC motif 
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prior to metal reconstitution. The buffer was then exchanged to 50 mM phosphate buffer at 
pH 7.2 to remove the excess of DTT using PD-10 desalting column or dialysis.  In order to 
obtain Cu(I)-, Cu(II)- and Ni(II)-metallated protein, progressive titration, monitored by 
UV-Visible spectroscopy or 1H-15N-HSQC experiment were performed, using the metals 
respectively in the  [Cu(I)(CH3CN)4]PF6, Cu2SO4 and NiCl2 forms. The titration was 
performed using a maximum protein concentration of 0.2 mM avoiding aggregation of the 
protein. The excess of metals was removed by PD-10 desalting column or dialysis. All the 
NMR samples were prepared in phosphate buffer at pH 7.2. Cu(I) metallation of human 
Cox17 (HCox17) was similarly performed in anaerobic condition. Compared to HSco 
protocol the HCox17 reduction was induced by lower amount of DTT (1 mM) and the 
metallation was performed at higher protein concentration (over 0.3mM). For the full 
metallation of HCox17 3:1 molar ratio (Cu:protein) where added due to the HCox17 lower 
affinity for Cu(I). Excess of Cu(I) was removed by PD10 or dialysis. Oxidation of HSco 
CXXXC motif was performed in diluted samples (0.02mM) by incubating the samples for 
over sixteen hour at room temperature exposed to air. The oxidation state of the HSco was 
checked by AMS reaction or 1H-15N-HSQC experiment.
2.7 Biochemical and biophysical characterization
2.7.1 Circular dichroism spectroscopy
Circular dichroism (CD) is a spectroscopy based on the differential absorption of 
left- and right-handed circularly polarized light. CD is an excellent tool for rapid 
determination of the secondary structure and folding properties (i.e.arrangement of peptide 
bonds in secondary protein structure elements like helices and strands) of proteins that 
have been obtained using recombinant techniques. One of most widely used application of 
CD in protein studies is to determine whether a purified protein is folded and how a 
mutation or conditions of sample (denaturant) affects its conformation or stability.
In proteins the major optically active groups are the amide bonds of the peptide 
backbone (peptide bond: absorption below 240 nm, aromatic aminoacid side chains: 
absorption in the range 260 to 320 nm and disulphide bonds: weak broad absorption bands 
centred around 260 nm), typically disposed in highly ordered arrays such as α-helices or b-
pleated sheets. A protein consisting of secondary structure elements will therefore display 
a spectrum that can be deconvoluted into the individual contributions; for this purpose 
several theoretical methods have been developed, all of them relying on the assumption 
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that the spectrum of a protein can be represented by a linear combination of the spectra of 
its secondary structural elements (% α-helix, % β-sheet and % random coil) [16].
Figure 2.4: CD spectra of poly-lysine in three conformations. The characteristic bands of secondary structure 
element are also indicated. Reprinted from Alliance protein laboratories home page [17].
In the current thesis CD spectroscopy was used to monitor the folding of proteins 
after their recombinant production. Moreover CD was used to monitor the effect of 
detergent in HSco proteins. CD measurements were performed with protein concentrations 
of 10-20uM . The CD investigations were carried out in a Jasco J-715 spectropolarimeter 
using a 0.1-cm pathlength cell with cooling jacket connected to a water thermostatic device 
at 25oC. Spectra were recorded from 190-250nm at a scan speed of 20 nm/min and resulted 
from averaging 4 scans. The final spectra were baseline-corrected by subtracting the 
corresponding buffer obtained under identical conditions. Results were expressed as the 
mean residue ellipticity [] at a given wavelength. The data were fitted with the secondary 
structure estimation program DicroProt [18] according to Yang et al. [19].
2.7.2 Dynamic light scattering 
Dynamic light scattering (DLS), also known as Photon correlation spectroscopy or 
Quasi-elastic light scattering is a technique which can be used to determine the size 
distribution profile of small particles in solution like proteins.
When light hits small particles the light scatters in all directions (Rayleigh 
scattering) so long as the particles are small compared to the wavelength (< 250 nm). If the 
light source is a laser, and thus is monochromatic and coherent, then one observes a time-
dependent fluctuation in the scattering intensity. These fluctuations are due to the fact that 
the small molecules in solutions are undergoing Brownian motion and so the distance 
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between the scatterers in the solution is constantly changing with time. This scattered light 
then undergoes either constructive or destructive interference by the surrounding particles 
and within this intensity fluctuation, information is contained about the time scale of 
movement of the scatterers. There are several ways to derive dynamic information about 
particles' movement in solution by Brownian motion. One such method is dynamic light 
scattering. The dynamic information of the particles is derived from an autocorrelation of 
the intensity trace recorded during the experiment. At short time delays, the correlation is 
high because the particles do not have a chance to move to a great extent from the initial 
state that they were in. The two signals are thus essentially unchanged when compared 
after only a very short time interval. As the time delays become longer, the correlation 
starts to exponentially decay to zero, meaning that after a long time period has elapsed, 
there is no correlation between the scattered intensity of the initial and final states. This 
exponential decay is related to the motion of the particles, specifically to the diffusion 
coefficient. The photon autocorrelation function from a system of monodisperse particles is 
given by a single exponential decay. The diffusion coefficient D can be determined by 
fitting the measured function to a single exponential. The hydrodynamic radius of particles 
Rh can be calculated from the Stokes-Einstein equation:
DTkR Bh 6/
where, kB is the Boltzmann constant (in J K
-1), η is the diluents’ viscosity (in kg/ms), D is 
the diffusion coefficient (in m2s-1) and T is the temperature in Kelvin. 
Figure 2.5: Diagram of light 
scattering in the chromatography 
mode. The protein sample is 
injected (injector), separated in 
the size-exclusion column. After 
elution the different properties 
of the protein are measured by 
the detectors.   Reprinted from 
Alliance protein laboratories 
home page  [17].
In the present thesis DLS was applied in chromatography mode (see Fig. 2.5) for 
the investigation of the aggregation state of the HSco constructs (SHSco1, LHSco1, 
SHSco2, LHSco2, see §3.3). 0.1–1 mM protein samples were injected on a Superdex75 
HR-10/30 size-exclusion column on an AKTAFPLC system (Amersham Pharmacia 
Biosciences) connected with a multiangle light scattering (DAWN-EOS, Wyatt 
_________________________________________________________________________
_________________________________________________________________________31
Technologies, Santa Barbara, CA) coupled with quasielastic light scattering detectors. Data
analysis and average MW were automatically calculated by the Wyatt's Astra software.
2.7.3 UV-visible spectroscopy
UV-visible spectroscopy involves the spectroscopy of photons in the UV-visible 
region. It uses light in the visible and adjacent near ultraviolet (UV) and near infrared 
(NIR) ranges. In this region of the electromagnetic spectrum, molecules undergo electronic 
transitions. UV-visible spectroscopy is routinely used in the quantitative determination of 
protein and DNA solution. Protein concentration can be determined by the absorption at 
280 nm (mainly due to Tyr and Trp residues) using the protein extinction coefficient 
(estimated by Protparam [20]) or by any colorimetric assay e.g. Bradford. The molar 
extinction coefficient (or molar absorptivity) is defined via the Beer-Lambert law:
lc /
where A absorbance, c the sample concentration (M) and l the length of light path through 
the sample in cm.
DNA quantification is based on the absorption purines and pyrmidines which show 
absorption maxima around 260nm (alternatively DNA can be quantified on agarose gel by 
ladder markers). In the present work UV-visible spectroscopy, apart for routine 
quantification, was used to monitor the metallation of HSco with Cu(II) and Ni(II), see 
§3.4. 
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3. Results
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3.1 Introduction
In this chapter are presented the results of my PhD thesis which involve a published 
article, a manuscript (status: submitted in JBC) and a last section with results on a project 
that is in progress. 
In the article under the title ‘Mitochondrial copper(I) transfer from Cox17 to 
Sco1 is coupled to electron transfer’ we show the that the Cox17 can transfer 
simultaneously copper(I) and two electrons to the human cochaperone Sco1 in the oxidized 
state. The same reaction of copper–electron-coupled transfer does not occur with the
human homolog of Sco1, HSco2. In the article are described a number of NMR titrations 
with labelled and unlabeled samples of HSco1, HSco2 and Cox17 but also electrospray 
ionization (ESI) MS experiments. For this article I was responsible for the production of 
the HSco1 and HSco2 proteins and the preparation of the samples of both Sco and Cox17 
in the appropriate metallation and  redox state before the NMR studies. 
In manuscript present in the §3.3 with the title ‘A 19aa segment promotes Sco1 
dimerization’ we characterized for the first time the interface of the Sco1 protein dimer 
using NMR spectra. A number of analytical gel filtration and light scattering data to verify 
the dimerization of the LHSco1 and the interaction between LHSco1 and LHSco2, were 
also performed. For this project I defined and cloned the LHSco1 construct, I altered and 
optimized the purification of the LHSco improving the stability and avoiding degradation
of the samples (see §2.4.), purified and prepared the samples needed for the experiments 
and finally performed the gel filtration and light scattering experiment.
In last section of this chapter ‘Production of human Surf1, Sco1 and Sco2 
transmembrane proteins’ I describe the production of the human Surf1, Sco1 and Sco2 
full length proteins showing that the proteins can be purified in the presence of specific 
detergents. For Sco proteins, this work primarily aims to investigate the possibility of 
dimerization of the HSco through their TM regions and for Surf1, the principal aim is to 
produce the protein for its structural characterization as it is not available. In this project I 
have cloned, produced and purified all proteins. Moreover, I screened and selected the 
appropriate detergents, in particular by investigating the folding state of the proteins by 
CD. 
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3.1 Mitochondrial copper(I) transfer from Cox17 to Sco1 is coupled to 
electron transfer.
The article can be found in the CD
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3.2 A 19aa segment promotes Sco1 dimerization 
Lucia Banci, Ivano Bertini, Theodoros Hadjiloi, Shenlin Wang
Magnetic Resonance Center CERM and Department of Chemistry, University of Florence, 
Scientific Campus, 50019, Sesto Fiorentino, Florence, Italy.
Abstract
Human Sco1 is a mitochondrial membrane bound protein involved in the assembly 
of the dinuclear CuA center in cytochrome c oxidase. The full length human Sco1 contains 
in the N-terminus a short matrix segment, a single transmembrane helix buried in the inner 
membrane and a soluble C-terminal domain extended into IMS. While previous structures 
determined for the soluble C-terminal domain show that this domain is monomeric, full 
length human Sco1 has been reported to function as homodimers. The structural 
information for dimeric human Sco1 is still unavailable. We report here that a 19-aa 
segment, rich in charged residues, linking the soluble C-terminal domain to the 
transmembrane helix, promotes human Sco1 dimerization in both the apo and the copper(I) 
form. The interface of dimeric Sco1, characterized by NMR spectra, contains residues of 
the N-terminus, metal binding site and their surroundings. A structural model for dimeric 
Sco1 is calculated accordingly. On the basis of our results, a mechanism of transferring 
copper cargos from human Sco1 to the binuclear CuA center is discussed.
Introduction
Cytochrome c oxidase (CcO) is the terminal enzyme of the respiratory chain in 
eukaryotes and a number of prokaryotes. Eukaryotic CcO is embedded in the inner 
mitochondrial membrane, where it catalyses reduction of molecular oxygen to water and 
pumps protons across the membrane[1-3]. Mammalian CcO consists of 13 subunits, three of 
which (CoxI-CoxIII) are encoded by the mitochondria genome and the remaining by the
nuclear genome [4]. The assembly of this enzyme is a complex, multistep process that 
involves at least 30 proteins [5-8]. Among them, the Sco family proteins, Sco1 and Sco2, are 
involved in the assembly of the CuA center, which is a binuclear copper center localized in 
the CoxII subunit [9]. Mutations in either Sco1 or Sco2 lead to decreased CcO activity and 
early death due to the failure of the holoenzyme assembly [10-13]. Studies with immortalized 
fibroblasts from SCO1 and SCO2 patients suggested that Sco1 and Sco2 have non-
overlapping but cooperative functions in CcO assembly [14].
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Human Sco1 and Sco2 have high sequence identity. Both proteins contain, after a 
short matrix segment, a single transmembrane helix (TM) in the N-terminal segment of the 
protein, anchoring them to the inner mitochondrial membrane, while the C-terminal 
domain is soluble and extended into the IMS. A 19-aa segment, rich in charged residues,
connects the TM and the soluble C-terminal domain of both Sco1 and Sco2 (Fig S1). In 
vivo and in vitro studies proved that the soluble C-terminal domain of human Sco1 and of 
Sco2 is able to bind one copper(I) ion in relatively high affinity via the CXXXCP motif 
and a His residue, both fully conserved [15-17]. Mutations of either these Cys or His residues 
abrogated the copper(I) binding ability and lead to a non-functional CcO [16], implying that 
the function of the Sco proteins is related to their metal binding ability.
The Sco proteins show a thioredoxin fold [18-23], i.e. that of proteins responsible of 
catalyzing the reduction of protein disulfides. This fold similarity suggested the possibility 
that Sco proteins could be involved also in thiol redox processes [23]. Recently, we have 
shown that, indeed, in prokaryotic organisms Sco1 is able to reduce oxidized CuA, while 
does not transfer copper(I) to it [24]. Thus in prokaryotic organisms its role is that of 
assisting the copper transfer process maintaining the copper bridging Cys of CuA in a 
reduced state [24]. At variance of prokaryotic, eukaryotic Sco1s have also the ability of 
binding copper(I) with high affinity thus suggesting for Sco1 a dual role , being both a 
copper chaperone and a thioredoxin. Recently, it has been also proposed that human Sco 
proteins might play a role in regulating the mitochondrial copper content, which is a 
further phenotype independent from that of the CcO assembly [25].
While the functional role of the soluble C-terminal domain of the Sco proteins has 
been investigated through structural and functional characterization [15,22], the role of the 
other parts of the proteins had not been specifically addressed. Size exclusion 
chromatography suggested that full-length human Sco proteins function as homodimers
[25]. However, the soluble C-terminal domain of human Sco1 and Sco2 proteins are both 
monomeric in solution, as proved by several techniques [15,19,20]. Thus, the N-terminal part 
of human Sco protein (either the matrix domain, the TM or the segment between the 
soluble C-terminal domain and the TM) has to be critical for protein association.
Furthermore, the segment between the soluble C-terminal domain and the TM is crucial for 
the Sco1 function. Indeed, in yeast Sco1, this cannot be replaced by its Sco2 counterpart
[26], while replacement of the TM with that of Sco2 maintain a fully functional Sco1. The 
segment linking the TM and the soluble C-terminal domain might therefore have a role for 
determining the spatial orientation of the soluble C-terminal domain and/or for modulating 
the aggregation state of the proteins [26].
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To test whether this segment has some role in protein self-association and/or mediate 
the formation of heterodimers between Sco1 and Sco2, we characterized two truncated 
forms of HSco1 and HSco2, lacking only the TM, the matrix domain and the proceeding
mitochondrial target sequence (MTS) (LHSco1 and LHSco2 hereafter). Constructs
contains, with respect to the constructs used for structure determination (called HSco1 and 
HSco2 hereafter), an additional 19-aa segment, which links the soluble C-terminal domain 
to the TM. From the present investigation, we found that the longer construct of human 
Sco1, but not that of Sco2, has tendency to dimerize both as apo and copper(I) loaded 
forms. The interface of dimeric LHSco1 contains long loop containing the fully conserved 
His residue, the flexible N-terminus, -7 and loop. 
Results
The aggregation state of Sco1 depends on the construct length 
Two truncated forms of the human SCO1 gene, both lacking the N-terminal 
mitochondrial targeting sequence, matrix segment and the single-transmembrane helix, 
have been engineered and characterized (Fig. S1). These forms differed by the presence
(LHSco1) or not (HSco1) of the 19-aa segment, which, particularly in Sco1, is rich in 
positively and negatively charged residues. Size-exclusion chromatography experiments in 
conjunction with multiangle light scattering measurements, showed that, while both the
apo and the copper(I) bound form of HSco1 eluted in a pure monomeric state in the 
concentration range have investigated (5 M to 20 M), with an average molecular weight 
of 20.0 kDa, the apo and the copper(I)-bound LHSco1 had a concentration dependent 
elution profile (Fig 1A and Table S4). Although they eluted as a single fraction, their
elution volumes indicated a protein size larger than the monomeric one, with the size 
increasing with concentration. These data suggested that LHSco1 has a tendency to 
partially form soluble homodimers, which are in fast equilibrium with the monomer. 
Consistently, the fitted molecular weight values, derived from light scattering data, also
showed a concentration dependent pattern. An average molecular weight of 24.9 kDa,
higher than the theoretical value of 22.1 kDa, was obtained for Cu(I)LHSco1 at 5 M 
concentration.
Since the additional 19-aa segment of LHSco1 is rich in charged residues, 
electrostatic interactions may play an important role in protein dimerization. Indeed, 
consistently with this hypothesis, the dependence of protein dimerization on salt 
concentration, as followed by multiangle light scattering measurements (Fig 1B), showed 
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that the average molecular weight of both forms of LHSco1 decreased with increasing of 
NaCl concentration.
The overall behavior of the two constructs of HSco1, therefore, suggests that the 
additional 19-aa segment is implicated in the formation of the dimeric form of LHSco1.
Both truncated human Sco2 forms are monomer in solution
Our previous work showed that HSco2 is monomeric in both apo and copper(I) loaded 
forms [20]. Size exclusion chromatography experiments performed on LHSco2 in its apo, 
Cu(I), forms, showed that, at variance with LHSco1, the two forms of LHSco2 have 
neither concentration dependent elution volumes nor experience formation of homodimers. 
The additional segment therefore does not affect the aggregation state of HSco2.
No evidence for stable complex LHSco1-LHSco2 heterodimer formation
Having shown that LHSco1 has tendency to form homodimers, we wanted then to address
the question of whether a stable LHSco1-LHSco2 heterodimer is formed. Size-exclusion 
chromatography on mixtures containing equimolar amounts of both proteins, either in the 
apo or in the Cu(I) bound forms, indicated that the proteins retained a molecular weight 
similar to those of the isolated proteins, suggesting that LHSco1 and LHSco2 do not 
interact or, if they do so, they form a very transient complex that cannot be detected 
through this analysis.
Structural and dynamical properties of apo and Cu(I)LHSco1 
NMR spectra, chemical shift perturbation mapping, and backbone amide 15N 
relaxation parameters of apo and Cu(I)LHSco1 at different concentrations were used to 
characterize the model of LHSco1 dimerization at the atomic level. Overall, 162 out of the 
expected 177 NH cross peaks were detected for Cu(I)LHSco1. Resonances were not 
detected for residues, from K-15 to K-11 and from K-3 to R1, located in the 19-aa 
additional segment, and I135 and M136, which were not observed also in Cu(I)HSco1[22]. 
Backbone chemical shifts of the soluble C-terminal domain of Cu(I)LHSco1 (0.1mM) 
were in very good agreements with those of Cu(I)HSco1, reported previously [22], 
indicating that the additional 19-aa segment does not affect Sco1 conformation.
A lower number of 1H-15N amide signals was detected in the apo form, as also found 
for apoHSco1[22]. Only 116 out of the expected 177 cross peaks were observed. In addition 
to those not observed in the Cu(I) bound form, resonances were not detected also for 
residues, L7-G10, Y35-F38, H40-L49, I73-D76, A110-M136 and F149-N152. The above 
residues comprise the N-terminal region, the CXXXCP metal-binding motif, loop 8, where
the metal binding His residue is localized, loop 5 and loop 10. This different behavior 
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between the apo and the copper bound forms is similar to our previous observation on the 
apo forms of HSco1 and HSco2 proteins [20,22]. Backbone chemical shifts of apoLHSco1 
match those of apoHSco1, indicating a similar overall conformation for the apo protein as 
well. The lack of several signals in the apo form originates from conformational disorder 
and/or exchange processes among multiple conformation states of the apo form. Upon 
metal binding, these regions take a more rigid conformation, as it occurs in HSco1 [22].
The NMR spectra of Cu(I)LHSco1 are concentration dependent with a number of 
peaks changing their shift as a function of protein concentration, consistent with monomer-
dimer equilibra, fast on the NMR time scale. The residues showing the largest combined 
chemical shift variations as a function of concentration are localized in the N-terminus of 
the construct (L7, G9 and G10), loop3 (H40), loop 8 (S118, H132, S133, and T134), -6 
(Y137), loop 9 (L144) and -7 (T146 and D147) (Fig 2A). With the exception of the 
residues on the -6, these residues are all solvent exposed and located on the same side of 
the protein surface (Fig 2B), suggesting that protein dimerization occurs in a specific 
manner, which involves the metal binding site, -7 and the N-terminus of the construct. In 
apoLHSco1, none of the residues experiencing chemical shift change in the Cu(I) bound 
form are detected. Therefore the concentration dependence of NMR spectra of apo form is 
not informative with respect to protein dimerization.
15N relaxation parameters on Cu(I)LHSco1, which were analyzed for 144 backbone 
NH groups, showed that the residues of the additional 19-aa segment are characterized by 
lower R2 and higher R1 values (Fig 3). These residues experience faster motions than the 
overall protein tumbling. The average values of R2 and R1 for the folded domain, estimated 
at 0.1mM concentration, are 24 ± 3 s-1 and 0.82 ± 0.15 s-1. 15N relaxation parameters are 
also concentration dependent, with higher R2 values in more concentrated sample (29 ± 3 s
-
1 and 0.79 ± 0.14 s-1 for 0.50 mM sample, Fig 3) These R2 values are significantly higher 
than those expected for monomeric HSco1 and lower than the values estimated for dimeric 
HSco1 (average R2 of 18 s
-1 and 34 s-1 for monomer and dimer, respectively). Also the 
experimental R1 values are lower than those expected for monomeric HSco1 and higher 
than the values for dimeric HSco1 (average R1 of 0.96 s
-1 and 0.50 s-1 for monomer and 
dimer, respectively). These data confirmed that Cu(I)LHSco1 is partially in a dimeric state 
with a fraction of about 40% dimer at 0.5mM protein concentration.
Concentration dependent relaxation rates were also obtained for apoLHSco1 (Fig 
S2); the average R1 and R2 values of apoLHSco1 are the same as those of Cu(I)LHSco1 
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measured in the same concentration, suggesting a formation of a similar fraction of dimeric 
form at the same concentration. 
Model of dimeric Cu(I)HSco1 
A structural model for dimeric Cu(I)HSco1, calculated on the basis of concentration 
dependent chemical shift data of Cu(I)LHSco1 (Fig 4) shows that dimerization occurs 
mainly through electrostatic interactions between the two monomers. At the dimer 
interface, D131, which is next to the metal binding His residue, forms salt bridges 
interactions with residues R154 and K153 of the other monomer. R114, at the beginning of 
loop 8, is involved in salt bridge interaction with E144 of the other monomer. The dimer is 
further stabilized by a hydrophobic patch, i.e. residue Y116 makes contact with Y148 of
the other monomer.
The distance between the N-terminus residues is 10-15 Ǻ, a distance which can be 
easily bridged by two stretches of 19 residues (Fig 4). The two metal binding sites are on
the same side of the dimer unit with a distance between the two copper ions of 20 Ǻ.  
Discussion
The N-terminus 19-aa segment of Sco1 which connects the folded C-terminal domain
with the TM helix, is responsible for the Sco1 tendency to dimerize. On the other hand, the 
same construct of Sco2 never forms dimeric species either with itself or with Sco1. It had 
been previously shown that Sco1, having the 19-aa segment substituted with that of Sco2, 
is not functioning in yeast [26], thus indicating that this segment has a key role in the in vivo 
Sco1 activity. As it comes out from the present results, its main role is that of modulating 
Sco1 dimerization, which involves the N-terminus, the solvent exposed loop containing the 
metal binding His residue and their surrounding. The driving force for protein dimerization 
resides in the additional 19-aa segment, which is rich in charged residues (10 positively
and 4 negatively charged residues). Several salt bridge interactions were also detected in 
the C-terninal folded domain in the structural model. The electrostatic driven interaction 
was also confirmed by the ionic strength dependence of protein dimerization. This high 
content in charged residues is also conserved in all the sequences of eukaryotic Sco1, but 
not in prokaryotic Sco proteins. Indeed the latter are proposed to be monomer [23].
Protein dimerization in the cell could be further strengthened by interactions between 
the two TM helices. Indeed, the latter are characterized by a side with several small 
residues, i.e. Gly and Ala, which are essential for stabilizing helix-helix interactions [27]. 
The two metal binding sites are on the same face of the dimer and located at the opposite
side with respect to the additional 19-aa segment linking the folded domain to the TM. 
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This location implies that the metal binding sites of dimeric HSco1 extend in the IMS, 
instead of facing the inner membrane of mitochondria. This conformation makes the 
copper ions bound to HSco1 for being transferred to the CuA site, which is 8 Ǻ outside the 
membrane surface [28]. We could also speculate that the two copper ions bound by dimeric 
Sco1 may transfer simultaneously to the CuA site.
Finally, LHSco2 is never present in a dimeric state in all the forms have investigated, 
i.e. apo, Cu(I), bound forms, nor it forms heterodimers with Sco1. The different behavior
with respect to Sco1 may arise from the lower number of charged residues (6 positively
and 3 negatively charged residues) in the additional 19-aa segment. The dimeric state, 
which had been observed in cell might be, however, formed through interaction between 
two TM, which, similarly to Sco1, feature a number of small residues on the same side. 
The soluble C-terminal domain of Sco2 has an internal dynamic and conformational 
disorder higher than that of Sco1[20].These two features, i.e. different dynamical and 
interaction properties, can contribute to make the dimeric state of Sco2 different from that 
of Sco1, thus contributing to differentiating the behavior and function of these two
otherwise similar proteins. 
Materials and Methods
Sample preparation
Two truncated forms of HSco1 and of HSco2 were prepared as described 
previously [22,22]. The Cu(I) metallated form was obtained by addition of stoichiometric 
amounts of the metal ions (Cu(I)(CH3CN)4)PF6) to diluted protein solutions in 50mM
phosphate buffer (pH 7.2), followed by protein concentration under nitrogen atmosphere.
Size exclusion chromatography and light scattering experiment procedure
All the size-exclusion chromatography experiments were done on a Superdex 75 HR-
10/30 size-exclusion column on an AKTA-FPLC system (Amersham Pharmacia 
Biosciences) connected to a multiangle light-scattering system (DAWN-EOS; Wyatt
Technologies) equipped with quasielastic light-scattering detector. The column was 
equilibrated with 50mM phosphate buffer (pH 7.2), containing 1mM DTT. A flow rate of 
0.5ml/min was used for all the studies. 100l protein solution was injected into the column. 
The loading concentrations had a range from 0.10 to 0.50 mM. The final concentrations of 
the eluted protein, estimated by the absorbance at 280 nm, had a range from 5 to 20 M. 
Elution profiles were obtained from the optical density values at 280 nm. The elution 
volumes were reported in Table S3 and Table S4.
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NMR spectroscopy
NMR spectra for backbone assignments were obtained through standard triple 
resonance experiments. The backbone assignment experiments of apo and Cu(I)LHSco1 
were performed on 0.50 mM samples at 500 MHz (298K) using standard pulse sequences. 
The relaxation data on apo and Cu(I)LHSco1 were obtained through 15N-R1 and 
15N-
R2 experiments at 700 MHz (298K) for samples containing 0.10 and 0.50 mM protein. 
Processing of NMR data was accomplished with the XWINNMR program. Relaxation 
parameters were determined by fitting the integration values obtained from XWINNMR 
program, measured as a function of the delay within the pulse sequence, to a single-
exponential decay.
HADDOCK docking calculations
HADDOCK calculations were performed with standard protocols (as described at 
www.nmr.chem.uu.nl/haddock/haddock.html [29]) to obtain a model of the dimeric form of 
the soluble C-terminal domain of Cu(I)HSco1. The best conformer of the solution 
structures of the Cu(I)SHSco1 (PDB code 2GT6) was used as the monomeric input. 
The "active" residues and "passive" residues were selected on the basis of the 
concentration dependent chemical shift variation (CSV) data of Cu(I)LHSco1. The high 
solvent accessible residues (>50%) that exhibited a CSV larger than average were 
designated as active residues and the residues neighboring those active residues with a high 
solvent accessibility (>50%) were designated as passive residues. The per residue solvent 
accessibility area was calculated by NACCESS program. 
In the first stage of the calculation, an initial set of 1000 rigid-body docking models 
was generated. The 200 lowest energy complex models were then selected and submitted 
for a second stage of calculations with semi-flexible simulated annealing. The 100 lowest 
energy models in the second stage were refined in water solvent. The final 100 calculated 
structures resulted all converge to a single ensemble of conformations, displaying a 
pairwise rms deviation <1.0 Å. The 20 lowest-energy structures were analyzed in terms of 
intermolecular contacts (hydrogen bonds and nonbonded contacts). 
HYDRONMR
Theoretical prediction of the relaxation parameters for monomeric and dimeric
Cu(I)HSco1 was calculated by using the ‘‘shell modeling’’ strategy implemented in
HYDRONMR software (30). The best represent conformer of solution structures of the 
Cu(I)HSco1 (PDB code 2GT6) was used to obtain expected relaxation values for 
monomeric Cu(I)HSco1. Those values for dimeric Cu(I)HSco1 were obtained by using the 
structural model of dimeric Cu(I)HSco1. The calculations were performed by using a 
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viscosity of water at 298K of 0.89 Ns/m2. The value of the atomic element radius was set 
to 3.3 Ǻ (30).
Figures and Tables
Figure 1: (A) Concentration dependent elution profiles of Cu(I)LHSco1 at two 
concentrations, 5 and 20 M, are shown. The elution profile for 5 M sample is scaled by 
a factor of four. (B) Salt dependence of the average molecular weight (MW) of LHSco1; 
Apo and Cu(I) LHSco1 are shown in “” and “▲”, respectively. The sample 
concentrations are 5 M.
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Figure 2: Chemical shifts of Cu(I)LHSco1 are concentration dependent. (A) Sequential
plot of combined chemical shift variations (CSV) between 0.10 and 0.50mM Cu(I)LHSco1 
is shown. (B) Residues showing CSV values above the threshold (> 0.015 ppm) are 
mapped in red on the structure of Cu(I)SHSco1. The copper binding Cys and His residues 
are shown in green and blue, respectively. Cu(I) ion is depicted in gold sphere.
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Figure 3: Sequential plot of concentration dependent 15N relaxation parameters for 
Cu(I)LHSco1. Data for 0.10 and 0.50 mM sample are shown in red and black, respectively. 
Figure 4: Model of dimeric Cu(I)HSco1. The two monomers are shown in green and grey, 
respectively. Copper ions are shown in gold. The copper binding Cys and His residues are 
shown in pink and blue, respectively. 
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Supplementary materials
Table S3. Elution volumes of Sco1 and Sco2 in different constructs and forms in 50mM 
phosphate buffer at 298K, pH 7.2.
                 Constructs
Elution volume (ml) a
Adducts
apo- Cu(I)-
HSco1 12.32 12.34
HSco2 12.52 12.56
LHSco2 12.25 12.24
LHSco1 11.45b 11.35b
a: The sample concentrations were 20M.
b: The value is for 20M conc. The elution volumes are concentration dependent (see Table S4).
Table S4. Elution volumes of apo and Cu(I)LHSco1 at different concentrations in 50mM 
phosphate buffer at 298K, pH 7.2
Elution volume (ml)
5 M 10 M 20 M
apo LHSco1 11.55 11.47 11.45
Cu(I)LHSco1 11.47 11.41 11.35
Figure S1: Protein sequence and cloned constructs of HSco1 and HSco2.
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Figure S2: Concentration dependent 15N relaxation parameters for apoLHSco1. Data for 
0.10 and 0.50 mM sample were shown in red and black, respectively.
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3.4 Production of human Surf1, Sco1 and Sco2 transmembrane proteins 
In the previous section  (see Results 3.3), we investigated the HSco oligomerization 
and the formation of a stable complex between the soluble domains, showing that these 
domains do not interact and HSco1 but not HSco2 forms dimeric species However, the 
interaction of the proteins and the dimerization of HSco2 maybe mediated through the TM
α-helices. In order to investigate the role this ΤΜ domain, human Sco1 (HSco1 hereafter) 
and Sco2 (HSco2 hereafter) containing the single TM α-helix were overexpressed in E.coli. 
Additionally, the full length human Surf1 (HSurf1 hereafter) containing two predicted TM 
α-helices was also tested for expression. In this section, we show the results of the 
overexpression of three human TM proteins, Sco1, Sco2 and Surf1 isolated from E.coli 
membranes. Having in mind of the difficulty of studying membrane proteins that contain 
soluble domain that tends to unfold in the presence detergent micelles, we have performed 
the initial purification of the TM heterologous proteins with detergents that do not unfold 
the soluble domain of the HSco proteins.
Introduction   
Cytochrome c oxidase (CcO) is the terminal enzyme of the energy-transducing  
respiratory chain in the mitochondria of eukaryotes and certain prokaryotes [1]. The 
eukaryotic enzyme catalyzes the reduction of molecular oxygen and couples this reduction 
with proton translocation across the inner membrane of mitochondria to generate the 
membrane potential necessary for ATP synthesis [2-4]. Eukaryotic CcO consists of 12 or 13 
subunits, with the three core enzyme subunits (Cox1–Cox3) being encoded by the 
mitochondrial genome. The catalytic cofactors in CcO include two modified heme moieties 
and three copper ions. One metal site, designated heme a3-CuB, is deeply buried within the 
Cox1 subunit. The other two copper ions exist in the binuclear CuA center within Cox2 
[5].
The assembly of the CcO complex requires various nuclear-encoded assembly 
factors. In yeast, more than 30 different protein factors for CcO assembly have been indeed 
identified [6].
Assembly of CcO is coordinated by two genomes (nuclear and mitochondrial) and 
consist of different steps, including the assembly of subunits translated on cytoplasmic and 
mitochondrial ribosomes, modification of protoheme to heme a, and the delivery and 
subsequent insertion of copper ions into the enzyme during the assembly process [7]. A 
number of copper chaperons, including Cox11, Cox17, Cox19, Cox23, Sco1, Sco2 are 
known to be important or have been implicated in the copper metallation of CcO [8,9]. 
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Copper insertion into Cox1 and Cox2 subunits occurs in the IMS, since the proteins are 
localized within this compartment. Cox11 and Sco proteins mediate the copper metallation 
of the CuB and CuA sites, respectively 
[10]. 
Sco1 and Sco2 are highly similar proteins but their distinct role in eukaryotic cells 
is still unclear [11]. Both proteins contain a single transmembrane (TM) α-helix at the N-
terminal segment, anchoring them to the IM while the C-terminal segment of Sco proteins 
is soluble and extended to the IMS. A highly conserved CXXXC motif and a conserved 
His residue form the copper binding site [12,13]. Structurally both proteins are characterized 
by a thioredoxin fold and with a single Cu(I) ion bound to be solvent exposed and poised 
for a ligand exchange transfer reaction. In vitro binding assays or gel filtration of 
mitochodrial extract showed that the eukaryotic Sco can form oligomeric and heteromeric 
complexes [11,14]. Interestingly, the ΤΜ α-helices of both proteins contain motifs that have a 
degree of propensity to promote TM helix-helix interaction [15-17]. Moreover, the ΤΜ
regions of human Sco proteins have lower similarity than the soluble domain; actually, the 
N-terminal part (matrix and TM α-helix) is the most diverse part of the two proteins. In 
vivo experiments in yeast showed that the TM α-helices and the matrix segment are 
important for the function of the proteins since only the full length proteins can mediate the 
formation of a functional CcO [11,18].   
Heme a biosynthesis and insertion is mediated by another group of assembly 
factors. Cox10 and Cox15, two intrinsic IM proteins catalyze the modification of 
protoheme to heme a by their successive catalytic action. Cox10 and Cox15 carry out the 
farnesylation and oxidation reactions, respectively [19,20]. Another assembly protein that 
that is necessary in this process is the Surf1 protein. The SURF1 gene was identified in a 
highly conserved cluster of housekeeping genes known as the surfeit locus, but its function 
remained unknown until pathogenic mutations in the gene were identified in CcO-deficient 
Leigh Syndrome (LS) patients [21]. The CcO deficiency in LS patients results from the 
failure in assembling physiological amount of active enzyme, suggesting a role for the 
Surf1 protein in the maturation of the CcO [22,23]. Moreover, in bacteria (R. sphaeroides and
P. denitrificans) Surf1 homologue gene deletion leads to misassembled CcO lacking the 
heme a3, suggesting that Surf1 (direct or indirect) mediate the insertion of heme a3 to the 
CcO [24,25]. The Surf1 protein is anchored to the IM by two predicted TM α-helices, one 
each at the N- and C-terminus of the protein. The extramembrane domain of the protein 
faces the IMS. Sequence alignments revealed many Surf1 homologues in eukaryotes and 
prokaryotes. They show a striking degree of homology, and all proteins exhibit the same 
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characteristic TM α-helical topology and two highly conserved regions in the soluble 
domain [26].
Results and discussion
Transmembrane HSco1, HSco2 and HSurf1 proteins as targets 
The transmembrane proteins selected for hetegologous expression, HSco1, HSco2 
and HSurf1 are involved in the assembly of the CcO. HSco1 and HSco2 are involved in the 
formation of the CuA site and HSurf1 is suggested to function during the folding of the 
Cox1 subunit [21]. Compared to Sco proteins whose soluble domains have been greatly 
investigated [12,13, 27-30], the Surf1 protein structure and biochemical characteristics remain 
unknown. On the other hand, the functional role of the TM α-helices of the Sco1 and Sco2 
is not known at the molecular level.  
Figure 1: Domain definition of human Sco1, Sco2 and Surf1 proteins. Two constructs for the human Sco1 
(FHSco1 and THSco1), one construct for the human Sco2 (FHSco2) and one construct for the human Surf1 
(HSurf1) were generated. In Sco proteins, the charged residue region at the C-terminus of the predicted TM 
α-helix (TM) is also shown. The CPXXCP motif of HSco and the two conserved regions at the soluble 
domain of HSurf1 are indicated with red underlined letters. MSP: mitochondrial signal peptide; Matrix: 
domain exposed to the matrix of mitochondrion; Soluble domain (IMS): soluble domain of the proteins 
exposed to the intermembrane space of mitochondrion.
We defined two constructs for the HSco1 (FHSco1 and THSco1) and one for 
HSco2 (FHSco2) as shown in Fig.1. The two full length protein constructs of the HSco 
proteins lack the predicted the mitochondrial signal peptide. The different size of the 
matrix domain of the HSco1 compared to HSco2 (61 vs 19 aa) and a predicted α-helix at 
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the position 34A-52A of HSco1 rationalize the selection of the extra construct for HSco1 
lacking the matrix domain of the protein (THSco1, Fig.1).  
The Surf1 protein is anchored to the IM by two predicted TM α-helices, one each at 
the N- and C-terminus of the protein. We defined one construct for the HSurf1 protein 
which lacks the mitochondrial signal peptide (FHSurf1) shown in Fig.1.
Production and localization of HSco1, HSco2 and HSurf1 transmembrane proteins 
The production of recombinant membrane proteins in E.coli has been recently 
tested (using 6His, Flag-peptide, MBP [31,32]), proving the possibility of producing high 
yields of membrane proteins for structural determination. 
Table 1: Production and localization of the HSco1, HSco2 and HSurf1 heterologous proteins
FHSco1 THSco1 FHSco2 FHSurf1
E M S E M S E M S E M S
6His + ++ -- -- -- -- -- -- -- -- -- --
GST + ++ + + ++ + -- -- -- -- -- --
Trx -- -- -- -- -- -- + -- -- -- -- --
MBP -- -- -- + ++ + + ++ + -- -- --
Msc + -- -- + -- -- + -- -- + -- --
GB1 -- -- -- -- -- -- + ++ + + ++ +
MBPperi -- -- -- -- -- -- -- -- -- -- -- --
* Abbreviations: E, production detected in the whole cell lysate; M, production detected in the cell 
membrane;  S, production detected in the soluble fraction, +, positive production; ++; positive production 
detected in the cell membranes; --, negative production.
We have tested the production of the HSco1, HSco2 and HSurf1 TM proteins fused 
with 6His, GB1, Trx, GST, MBP, MBPperi and Msc, considering as positive result only 
the detection of the proteins in the cell membrane. The three strains tested (BL21-
Gold(DE3), C41(DE3), C43(DE3) ) showed different profile of production and 
localization. The C41(DE3) strain was found to produce high amount of protein in 
inclusion bodies and was no further used. The BL21-Gold and C43(DE3) strains had 
similar production profile but different protein production levels. C43(DE3) strain
produced higher amount the target proteins and was chosen for further analysis. In Table 1 
are shown the production and localization results of heterologous TM proteins expressed in 
the C43(DE3) strain. From the 28 fused proteins tested only the 7 have been detected in the 
cell membrane, without any preference in fusion protein or protein target. Moreover, when 
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the proteins are detected in the cell membranes they are also detected in the soluble 
fraction (5-10 fold higher amounts), except the 6His-FHSco1, which is only detected in the 
cell membrane. Finally, the Trx, Msc, and MBPperi fused TM proteins were not detected 
in the cell membranes.
Detergent selection: Effect of detergent micelles on HSco soluble domain 
In NMR studies of membrane proteins, a number of detergents have been used with 
success largely limited to small-micelle detergents with small or charged headgroups such 
as dodecylphosphocholine (DPC), Lyso-palmitoyl phosphatidylcholine (LPPC), Lyso-
myristoyl phosphatidylglycerol (LMPG) sodium dodecylsulfate (SDS), N-lauroylsarcosine, 
lauryldimethylamine oxide (LDAO) and octylglucoside [33,34]. The selection of the more 
suitable detergent greatly depended on monitoring the stability and folding of the 
membrane protein [35].
Figure 2: Overlay of 1H-15N HSQC spectra of 15N-LHSco1Cu(I) (red) with: A) 15N-LHSco1Cu(I)/OG 
micelles, B) 15N-LHSco1Cu(I)/DPC micelles. Concentration of detergent: OG 1.0% and DPC 0.26% 
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Figure 3: CD spectra of LHSco1 and LHSco2 in detergent micelles. DDM 0.02%, DPC 0.1%, LDAO 
0.06%, OG 1.0%.
The TM proteins have a soluble domain that should behave differently in detergent 
micelles compared to the TM domain. An ideal detergent for the HSco and HSurf1 TM 
proteins would be a detergent that do not unfold the soluble domain and stabilize the TM 
helices avoiding aggregation. 
In order to choose the detergent for the purification of the membrane proteins we 
tested the effect of the detergent micelles on the soluble domain of HSco and the ability of 
HSco to be metallated in the presence of detergent micelles. 
Figure 4: UV-Visible spectra of Cu(II)HSco soluble domain (LHSco1) in DDM micelles. The electronic 
spectra of the LHSco1 after metallation (1:1 Cu(II): protein ratio) in the presence and absence of detergent
micelles showing the characteristic absorbance at 360, 470 and 610nm.
The NMR (Fig. 2) and CD (Fig. 3) spectra collected show that zwitterionic 
detergents (like DPC and LDAO) unfolds the soluble domain of HSco. Although the CD 
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spectra of both HSco indicate that the secondary structure elements are different but not 
lost with respect to that present in the absence of detergents, the 1H-15N-HSQC spectra 
show the unfolding of the HSco soluble domain. On the other hand, the two non-ionic 
detergent (OG, DMM) micelles do not unfold the soluble domain and are proven to be the 
best choice for the purification of the TM proteins. Additionally, the metallation of HSco 
in non-ionic detergents indicates that the proteins are well folded (Fig. 4).  
Purification and cleavage of the fused transmembrane proteins
Three non-ionic detergents OG, DM, and DDM were chosen for the purification of 
the seven positive fusion proteins detected in the E.coli cell membrane. These detergents 
have different characteristics mainly due to the size alkyl chain, with OG having the 
shortest (C8) and the higher CMC value (25mM) compared to DM (C10) and DDM (C12) 
that have 10- and 100-fold lower CMC values, respectively. The length of the alkyl chain 
affects also the aggregation number and the size of the micelles formed. OG forms the 
smallest micelles with an average size of 23kDa.
Upon purification of the target proteins, the detergents were evaluated for their 
effect on the targets stability and TEV activity. OG was found to destabilize the purified 
proteins and cause precipitation of all the targets. Moreover, there was no indication of 
cleavage when the samples were incubated with TEV protease in the presence of OG. In 
the presence of DM and DDM the purified proteins were stable and the cleavage of certain 
fused proteins was also detected. The results are shown in Table 2.
Table 2: Purification and digestion of target proteins in the presence of DM and DDM micelles
Target Fusion protein    
(MW, kDa)
Purification
(yield, mg)
TEV digection %
DM DMM
His-FHSco1
GST-FHSco1
GST-THSco1
MBP-THSco1
MBP-FHSco2
GB1-FHSco2
GB1-FHSurf1
34.1
57.6
51.2
66.4
67.6
35.1
38.9
n/a
n/a
3
3
4
3
5
n/a
0
0
70
70
50
50
n/a
0
0
70
70
50
50
The amount of protein was determined by absorbance at 280 nm after eluting the sample from the metal 
affinity column. Abbreviations are as follows: MW, molecular weight; n/a, not applicable.
Typically, high yields (>5mg/L of the target protein) are desirable for structural 
studies. The yields of the purified protein obtained from 1L LB cultures are shown in Table 
2. The yield can be further improved by longer incubation of the targets to the resin during 
the purification since, due to inefficient binding in presence of detergents, unbound protein 
accounts to 90% . 
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Conclusions 
The three TM proteins, HSco1, HSco2 and HSurf1 were produced as fused proteins 
and detected in the cell membrane of the E.coli. The purification trails with selected 
detergent showed that some of the targets (like MBP-THSco1, MBP-FHSco2, GB1-
FHSco2 and GB1-FHSurf1) can be purified. Biophysical tools (NMR, CD and light 
scattering) are now used to characterize the produced proteins.   
Materials and methods
Detergents: Octylglucoside(OG), Decylmaltoside (DM), Dodecylmaltoside (DDM), 
Dodecylphospho- choline (DPC), N-Lauroyldimethyl amineoxide(LDAO), where 
purchased from Glycon Biochemical. Vectors were purchased form European Molecular 
Biology Laboratory Protein Expression and Purification Facility apart from the homemade 
pDEST-Mistic.
Definition of constructs 
The transmembrane (TM) regions of the HSco1 (NP_004580), HSco2 
(NP_005129) and HSurf1 (NP_003163) proteins were predicted using TMbase [37], PRED-
TMR [38] and TMHMM2.0 programs [39]. The mitochondrial signal peptide was predicted 
using MitoProt II 1.0a4 program [40]. Rare condons determination by Rare Codon 
calculator (RaCC). Disordered regions were predicted using IUPred [41]. The designed 
constructs are: the full length human Sco1 lacking the predicted mitochondrial signal 
peptide, 31G-301S, (FHSco1 hereafter), the human Sco1 lacking the predicted 
mitochondrial signal peptide and the matrix segment, 90G-301S, (THSco1 hereafter), the 
full length human Sco2 lacking the predicted mitochondrial signal peptide, 45G-266S 
(FHSco2 hereafter) and full length human Surf1 lacking the predicted mitochondrial signal 
peptide: 45G-300V (FHSurf1 hereafter). Constructs are shown in Fig.1. 
Cloning
The cDNA of human SCO1, SCO2 and SURF1 (purchased from RZDB, Germany) 
were amplified by PCR. The constructs were inserted in Gateway Entry vector 
pENTR/TEV/D-TOPO (Invitrogen) and sequences were verified by sequencing at PRIMM 
(PRIMM, Italy). The pENTR clones were recombinated with pETG-30A (6His-GST, GST 
hereafter), pDEST-17 (6His), pDEST-HisMBP (6HisMBP, MBP hereafter), pDEST-
periHisMBP, (6HisMBP, MBPperi hereafter), pTH34 (6His-GB1, GB1 hereafter), 
pETG20A (6HisTrx, Trx hereafter) and pDEST-Mistic (6HisMistic, Msc hereafter). 
Insertion of the DNA constructs was verified by PCR screening and the plasmid of the 
positive clones was purified using the QIAquick PCR Purification Kit (Qiagen) to 
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transform BL21-Gold(DE3) (Stratagene), BL21(DE3) C43 (Avidis) and BL21(DE3)C41 
(Avidis) cells. 
Protein production screening 
The cells were grown in LB medium at 30 °C until the cell cultures reached the 
OD600 of ~0.6. The cultures were then cooled down to 18°C and induced with 0.2 mM 
isopropyl-b-D-1-thiogalactoside (IPTG). Cell cultures were harvest after overnight 
incubation at 18°C. Protein production was first tested in 5 mL cultures. Clones that 
showed heterologous protein production were grown in 100 mL cultures. The cell pellet 
obtain was analysed for protein expression in the soluble and membrane fraction of the cell 
lysate. Clones that the heterologous protein was detected in cell membranes were grown in 
1L culture for protein purification. Heterologous protein production of the target proteins 
was detected via SDS-PAGE.
Cell lysis, membranes isolation and protein purification
Frozen cell pellets were resuspended in 20 mM Tris-HCl, 100 mM NaCl, pH 7.5 
(B-buffer)  1 mg/mL lysozyme, complete protease inhibitor cocktail EDTA-free (Roche). 
After sonication (5 times 30 sec/5 min pause) the suspension was centrifuged at 15,000 g
for 15min to remove inclusion bodies and unbroken cells. The cell membranes were 
isolated by 1 h centrifugation at 150,000g. The membranes were resuspended (using a 
glass homogenizer) in B-buffer and solubilized by addition of detergent and incubated for 
2h, followed by centrifugation for 45 min at 200,000 g. The supernatants containing 
solubilized membrane proteins were diluted (with B-buffer to reach the working 
concentration of detergent) and incubated 1h with metal chelating agarose resin (Ni2+ was 
used for Surf1 and Zn2+ for Sco proteins) pre-equilibrated with the B-buffer, including 5 
mM of imidazole and the corresponding detergent. The resin was washed with the B-buffer 
containing 10 mM of imidazole and the corresponding detergent. The recombinant proteins 
were eluted with 300 mM of imidazole in the same buffer supplemented with 1mM 
dithiothreitol (DTT). Tobacco etch virus (TEV) protease cleavage of the fusion proteins 
was perfomed in B-buffer supplemented with 1 mM DTT, 0.5 mM EDTA and the 
corresponding detergent. The yields were calculated by measuring the absorbance at 280 
nm. 
HSco folding characterization in detergent micelles
Human Sco1 and Sco2 soluble domain (113K-301S: LHSco1, and 79R-266S: 
LHSco2) were expressed, purified and metallated with Cu(I) or Cu(II) according to already 
reported protocol [12]. 15N-LHSco1-Cu(I) sample in phosphate 50 mM, 1 mM DTT, pH 7.2 
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was mixed with the corresponding detergent. The final concentration of protein was 0.1 
mM. The final concentration of detergent ( CD ) used was based on the formula 
[34]: 
 PnumD CACMCC 
where CMC, critical micelle concentration of detergent; Anum, aggregation number of 
detergent in a micelle and Cp, the concentration of the protein. 
1H-15N-HSQC spectra were 
collected at 298 K on Avance 800 spectrometer. CD measurements of apo LHSco1 and 
LHSco2 were performed with protein concentrations of 10 uM in 10 mM phosphate buffer, 
pH 7.2 and the corresponding detergent ( CMCCD  5.1 ). The CD investigations were 
carried out in a Jasco J-715 spectropolarimeter using a 0.1-cm pathlength cell with cooling 
jacket connected to a water thermostatic device at 25oC. Spectra were recorded from 190-
250nm at a scan speed of 20 nm/min and resulted from averaging 4 scans. The final spectra 
were baseline-corrected by subtracting the corresponding buffer obtained under identical 
conditions. Results were expressed as the mean residue ellipticity [] at a given 
wavelength. Electronic spectra of the Cu(II) form of the HSco after metallation with 
CuSO4 (1:1.2 protein:Cu ratio) in detergent micelles were recorded on a Cary 50 
spectrophotometer (Varian) using 50 uM protein concentration and detergent concentration 
according to the formula above.
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4. Conclusions and perspectives
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Structural biology seeks to understand the structure and function of 
macromolecules through structure determination by X-ray crystallography, NMR, electron 
microscopy, theoretical analyses, and a wide range of correlative biochemical and genetic 
studies of function. In recent years, the analysis of metalloenzymes and metalloproteins has 
accelerated[1]. Many developments and initiatives have taken place, particularly due to 
progress in X-ray and NMR studies, in order to clarify the role and trafficking of the 
metals in the cell. 
Cytochrome c oxidase (CcO), the last enzyme of the respiratory chain, is a member 
of a superfamily of heme-copper-containing terminal oxidases that are present in all 
aerobic organisms. Defects involving genetic mutations altering CcO functionality or 
structure can result in severe, often fatal metabolic disorders. Among the many classified 
mitochondrial diseases, those involving dysfunctional CcO assembly are thought to be the 
most severe. Currently, mutations have been identified in six CcO assembly factors: 
SURF1[2], SCO1[3], SCO2[4], COX10[5], COX15[6], and LRPPRC[7]. Mutations in these 
proteins can result in altered functionality of sub-complex assembly, copper transport, or 
translational regulation. 
During my PhD course, research was focused on clarifying the functional role of
human Sco1, Sco2 and Cox17 in CuA site of CcO assembly mechanism, and the production 
of the Surf1 protein.
The formation of the CuA site of CcO proceeds through protein-protein interaction  
processes involving Cu(I) transfer from Cox17 to the Sco proteins and finally to the apo 
CuA site. In this process, Sco1 and Sco2 are working cooperatively with non-overlapping 
functional role [8]. We investigated the metal transfer between the human Sco proteins and 
the human Cox17, showing that mitochondrial Cu(I) transfer from Cox17 to Sco1 can be
coupled to electron transfer and  the same reaction does not occur in Sco2. The different 
redox behaviour of Sco1 compared to Sco2 can strongly contribute to define the molecular 
basis of the functional differentiation of the two proteins. The electron transfer-coupled 
metallation mechanism could occur within the IMS for an efficient specific transfer of the 
metal to the proteins, when metal-binding thiols of CuA site are oxidized.  
The human Sco proteins are detected as dimeric proteins. The dimeric aggregation 
state and the formation of a Sco1/Sco2 heterodimeric complex were suggested to be the 
key complex for the formation of the bimetallic CuA site
[8,9]. We investigated the 
aggregation state of the soluble domain of human Sco, showing that a 19aa segment 
promotes the dimerization of human Sco1, but not human Sco2. The investigation of the 
apo and Cu(I) forms showed that the Sco1 dimerization is driven by the charged residue of 
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the 19aa segment at the N-terminus and the dimer is orientated in such way that the copper 
sites are close and solvent exposed. The dimeric Sco1 strongly supports the model of 
simultaneous transfer of two copper ions to the apo CuA site. Moreover, the formation of a 
stable heterocomplex between human Sco1 and Sco2 soluble domain was also 
investigated, showing that these soluble domains do not interact. However, the interaction 
between the two proteins and the dimerization of human Sco2 maybe reside in the TM 
segments. To investigate this matter, the human Sco1 and Sco2 containing their single 
transmembrane α-helix were expressed and extracted from the cell membranes of E.coli.
Following steps will be to characterize them by NMR and investigate their interaction at a 
molecular level.
From our data, the distinct functional role of human Sco1 and Sco2 can be related 
to the observed different behaviour related to their redox properties when interacting with 
Cox17 as well as to their aggregation state. Human Sco1 and Sco2 function should be more 
deeply investigated at the molecular level. The interaction of the human Sco proteins with 
the CuA site can definitively unravel the "mystery" of the mechanism of the insertion of 
copper and the different function of each Sco in this process. The role of the human Cu(II) 
Sco form is also unknown. Does this form exist in the mitochondria? And if it does, how is 
it formed since Cox17 transfer exclusively Cu(I) ions? Further studies on the Cu(II) form 
of the Sco proteins are necessary to clarify the role of this controversial state.
Surf1 is a transmembrane protein anchored to the mitochondrial inner membrane 
by two transmembrane α-helices. The protein is involved in the folding of Cox1 subunit 
and suggested to mediate the heme a3 insertion. Apart from the implication of the protein 
in the mitochondrial diseases, the biochemical and structural characteristics of the protein 
are unknown. We expressed the Surf1 transmembrane protein in E.coli and detected 
production in the cell membrane. The biochemical and structural characterization of the 
protein will be the next step.
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